Clinical Trial: A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction

U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269717) titled 'A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction' on Nov. 26.

Brief Summary: This study aims to evaluate the safety and tolerability of HRS-1893 in subjects with heart failure with preserved ejection fraction.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Heart Failure With Preserved Ejection Fraction

Intervention: DRUG: HRS-1893 Tablet

HRS-1893 tablet.

DRUG: HRS-1893 Tablet Placebo

HRS-1893 tablet placebo.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shandong Suncadia Medicine Co., Ltd.

Published by HT Digital Content Services with permission...